| Identification | Back Directory | [Name]
Durlobactam sodium salt (Synonyms: ETX2514) | [CAS]
1467157-21-6 | [Synonyms]
ETX2514
Durlobactam sodium salt
Durlobactam sodium salt (Synonyms: ETX2514) | [Molecular Formula]
C8H12N3NaO6S | [MDL Number]
MFCD31813710 | [MOL File]
1467157-21-6.mol | [Molecular Weight]
301.25 |
| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to light yellow | [InChI]
InChI=1/C8H11N3O6S.Na.H/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16;;/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16);;/t5-,6+;;/s3 | [InChIKey]
VSMSKKZAPNCKDR-GFXHAONCNA-N | [SMILES]
C([C@@H]1C(=C[C@H]2N(OS(O)(=O)=O)C(=O)[N@@]1C2)C)(=O)N.[NaH] |&1:1,4,13,r| |
| Hazard Information | Back Directory | [Uses]
Durlobactam sodium salt (ETX2514) is a broad-spectrum β-lactamase inhibitor with IC50s of 4, 14 and 190 nM for Class A KPC-2, Class C AmpC and Class D OXA-24, respectively. For the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii[1]. | [in vivo]
Durlobactam sodium salt (ETX2514) (50 mg/kg, 200 mg/kg; sc; single dose) effectively inhibits Acinetobacter baumannii in a neutropenic mouse thigh infection model (mice carrying blaTEM-1, blaADC-82, blaOXA-23, and blaOXA-66)[3].
| [References]
[1] Durand-Réville TF, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017 Jun 30;2:17104. DOI:10.1038/nmicrobiol.2017.104
[2] González-Bello C. Recently developed synthetic compounds with anti-infective activity. Curr Opin Pharmacol. 2019 Oct;48:17-23. DOI:10.1016/j.coph.2019.03.004
[3] Barnes MD, et al. Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. mBio. 2019 Mar 12;10(2):e00159-19. DOI:10.1128/mBio.00159-19 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|